RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

In a report released today, Lisa Walter from RBC Capital reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $40.00. The company’s shares closed last Friday at $26.35.

According to TipRanks, Walter is a 4-star analyst with an average return of 97.1% and a 100.00% success rate.

4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.50, an 87.86% upside from current levels. In a report released today, Barclays also assigned a Buy rating to the stock with a $45.00 price target.

Based on 4D Molecular Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $32.28 million. In comparison, last year the company earned a revenue of $1.25 million and had a GAAP net loss of $27.38 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

4D Molecular Therapeutics (FDMT) Company Description:

4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.